Montrouge, France, April 26, 2022 (01:30 CET)
DBV
Technology
presents its financial results for
first
quarter 2022
and review its activities
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will host a conference call and live audio webcast on Monday, Mar 2, 2022 at 11:00 p.m. ( CEST) to present the financial results for the first quarter of 2022 and to provide an update on its activities.
The conference call can be accessed via the teleconference numbers below, followed by reference ID: 89119188.
USA: 866 374 5140
Canada: 866 455 3403
UK: 808 238 9813
France: 805 102 712
The call will be broadcast live on the company’s website, in the “Investors and Press” section: https://www.dbv-technologies.com/fr/investor-relations/ . A replay of the presentation will also be available on the DBV website after the event.
HAS
in relation to
DBV Technologies
DBV Technologies is developing Viaskin™, an exclusive experimental technology platform with vast fields of potential applications in immunotherapy. Viaskin™, uses epicutaneous immunotherapy, or EPIT™, which is the method developed by DBV to deliver biologically active compounds to the immune system through intact skin. With this new category of non-invasive product candidates, the Company aims to safely transform the management of patients suffering from food allergies. DBV Technologies’ food allergy programs include ongoing clinical trials of Viaskin™ Peanut. DBV Technologies has a global headquarters in Montrouge (France) and a North American operational structure in Basking Ridge, New Jersey. The Company’s ordinary shares are traded on the B segment of Euronext Paris (ticker: DBV, ISIN Code: FR0010417345), while the Company’s ADSs (each representing half of an ordinary share) are traded on the Nasdaq Global Select Market (ticker: DBVT).
Contact
Investors
Anne Pollack
DBV Technologies
+1 857-529-2363
[email protected]
Media contacts
Angela Marcucci
DBV Technologies
+1 646-842-2393
[email protected]
Enclosed